Overview of experimental and conventional pharmacological approaches in the treatment of sleep and wake disorders

Current Topics in Medicinal Chemistry

Volumn 8, Issue 11, 2008, Pages 937-953

  Renger, John J ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE   (United States)

Author keywords

CNS; Excessive daytime sleepiness; Hypothalamus; Insomnia; Sleep

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ALPRAZOLAM; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BROMPHENIRAMINE; CLONAZEPAM; CX 717; DIAZEPAM; DIMENHYDRINATE; DIMETAPP; DIPHENHYDRAMINE; DOXYLAMINE; ESTAZOLAM; GLUTAMATE RECEPTOR AGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; HORMONE RECEPTOR BLOCKING AGENT; MELATONIN DERIVATIVE; MIDAZOLAM; NYQUIL; OREXIN ANTAGONIST; OXAZEPAM; OXYBATE SODIUM; PARACETAMOL; PICROTOXIN; PROSTAGLANDIN D2; RAMELTEON; SEROTONIN 2A ANTAGONIST; SEROTONIN ANTAGONIST; SINGLET; TEMAZEPAM; TRAZODONE; TROPISETRON; UNINDEXED DRUG; ZALEPLON; ZOLPIDEM; ZOLPIDEM TARTRATE;

ALCOHOL CONSUMPTION; ANIMAL MODEL; ARCUATE NUCLEUS; CATAPLEXY; CIRCADIAN RHYTHM; CIRCADIAN RHYTHM SLEEP DISORDER; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DELAYED SLEEP PHASE SYNDROME; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ELECTROENCEPHALOGRAPHY; ENVIRONMENTAL FACTOR; FATAL FAMILIAL INSOMNIA; GENE LOCUS; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; HYPNOGRAM; HYPOTHALAMUS NUCLEUS; INSOMNIA; NARCOLEPSY; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; PREOPTIC NUCLEUS; REVIEW; SIDE EFFECT; SLEEP APNEA SYNDROME; SLEEP DISORDER; SLEEP WAKING CYCLE; SOMNOLENCE; SUPRACHIASMATIC NUCLEUS; THALAMOCORTICAL TRACT; WAKEFULNESS;

ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CIRCADIAN RHYTHM; HUMANS; HYPNOTICS AND SEDATIVES; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; WAKEFULNESS;

EID: 48249105817     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802608784936755     Document Type: Review

References (108)

1. Banks, S.; Dinges, D.F. Behavioral and physiological consequences of sleep restriction. J. Clin. Sleep Med. 2007, 3(5), 519-28.
2. Carskadon, M.A.; Dement, W.C. Cumulative effects of sleep restriction on daytime sleepiness. Psychophysiology 1981, 18(2)107-13.
3. Chasens, E.R. Obstructive sleep apnea, daytime sleepiness, and type 2 diabetes. Diabetes Educ. 2007, 33(3), 475-82.
4. Knutson, K.L.; Spiegel, K.; Penev, P.; Van Canter, E. The metabolic consequences of sleep deprivation. Sleep Med. Rev. 2007, 11(3), 163-78.
5. Punjabi, N.M.; Polotsky, V.Y. Disorders of glucose metabolism in sleep apnea. J. Appl. Physiol. 2005, 99(5), 1998-2007.
6. Spiegel, K.; Knutson, K.; Leproult, R.; Tasali, E.; Van Cauter, E. Sleep loss: A novel risk factor for insulin resistance and Type 2 diabetes. J. Appl. Physiol. 2005, 99(5), 2008-19.
7. Brisbare-Roch, C.; Dingemanse, J.; Koberstein, R.; Hoever, P.; Aissaoui, H.; Flores, S.; Mueller, C.; Nayler, O.; van Gerven, J.; de Haas, S.L.; Hess, P.; Qiu, C.; Buchmann, S.; Scherz, M.; Weller, T.; Fischli, W.; Clozel, M.; Jenck, F. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat. Med. 2007, 13(2), 150-5.
8. Borbely, A.A. A two process model of sleep regulation. Hum. Neurobiol. 1982, 1(3), 195-204.
9. Edgar, D.M.; Dement, W.C.; Fuller, C.A. Effect of SCN lesions on sleep in squirrel monkeys: Evidence for opponent processes in sleep-wake regulation. J. Neurosci. 1993, 13(3), 1065-79.
10. Konopka, R.J.; Benzer, S. Clock mutants of Drosophila melanogaster. Proc. Natl Acad Sci. USA 1971, 68(9), 2112-6.
11. Naylor, E.; Bergmann, B.M.; Krauski, K.; Zee, P.C.; Takahashi, J.S.; Vitatema, M.H.; Turek, F.W. The circadian clock mutation alters sleep homeostasis in the mouse. J. Neurosci. 2000, 1(21), 8138-43.
12. Shearman, L.P.; Jin, X.W.; Lee, C.G.; Reppert, S.M.; Weaver, D.R.; Targeted disruption of the mPer3 gene: Subtle effects on circadian clock function. Mol. Cell. Biol. 2000, 20(17), 6269-75.
13. Saper, C.B.; Lu, J.; Chou, T.C.; Gooley, J. The hypothalamic integrator for circadian rhythms. Trends Neurosci. 2005, 28(3), 152-7.
14. Rechtschaffen, A.; Kales, A. A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subject. US Government Printing Office, National Institute of Health Publication, Washington DC, 1968.
15. Steriade, M.; McCormick, D.A.; Sejnowski, T.J. Thalamocortical oscillations in the sleeping and aroused brain. Science 1993, 262(5134), 679-85.
16. Dauviltiers, Y.; Maret S.; Tafti, M. Genetics of normal and pathological sleep in humans. Sleep Med. Rev. 2005, 9(2), 91-100.
17. Gambetti, P.; Parchi, P.; Chen, S.G. Hereditary Creutzfeldt-Jakob disease and fatal familial insomnia. Clin. Lab. Med. 2003, 23(1), 43-64.
18. Montagna, P.; Fatal familial insomnia: A model disease in sleep physiopathology. Sleep Med. Rev. 2005, 9(5), 339-53.
19. Webb, W.B.; Campbell, S.S. Relationships in sleep characteristics of identical and fraternal twins. Arch. Gen. Psychiatry 1983, 40(10), 1093-5.
20. Lin, L.; Faraco, J.; Li, R.; Kadotani, H.; Rogers, W.; Lin, X.; Qiu, X.; de Jong, P.J.; Nishino, S.; Mignot E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor2 gene. Cell 1999, 698(3), 365-76.
21. Chemelli, R.M.; Willie, J.T.; Sinton, C.M.; Elmquist JK, Scammell, T.; Lee, C.; Richardson, J.A.; Williams, S.C.; Xiong, Y.; Kisanuki, Y.; Fitch, T.E.; Nakazato, M.; Hammer, R.E.; Saper, C.B.; Yanagisawa, M. Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. Cell 1999, 20(4), 437-51.
22. Nishino, S.; Ripley, B.; Overeem, S.; Lammers, G.J.; Mignot, E. Hypocretin (orexin) deficiency in human mrcolepsy. Lancet 2000, 355(9197), 39-40.
23. Peyron, C.; Faraco, J.; Rogers, W.; Ripley, B.; Overeem, S.; Charnay, Y.; Nevsimalova, S.; Aldrich, M.; Reynolds, D.; Albin, R.; Li, R.; Hungs, M.; Pedrazzoli, M.; Padigaru, M.; Kucherlapati, M.; Fan, J.; Maki, R.; Lammers, G.J.; Bouras, C.; Kucherlapati, R.; Nishino, S.; Mignot E. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 2000, 6(9), 991-7.
24. Mignot, E.; Lin, L.; Rogers, W.; Honda, Y.; Qiu, X.H.; Lin, X.Y.; Okun, M.; Hohjoh, H.; Miki, T.; Hsu, S.H.; Leffell, M.S.; Grumet, F.C.; Fernandez-Vina, M.; Honda, M.; Risch, N. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am. J. Human Genet. 2001, 68(3), 686-99.
25. Ueno, R.; Ishikawa, Y.; Nakayama, T.; Hayaishi, O. Prostaglandin- D2 Induces Sleep When Micro-Injected Into the Preoptic Area of Conscious Rats. Biochem. Biophys. Res. Commun. 1982, 109(2), 576-82.
26. Huang, Z.L.; Urade, Y.; Hayaish, O. Prostaglandins and adenosine in the regulation of sleep and wakefulness. Curr. Opin. Pharmacol. 2007, 7(1), 33-8.
27. Jordan, W.; Tumani, H.; Cohrs, S.; Eggert, S.; Rodenbeck, A.; Brunner, E.; Ruther, E.; Hajak, G. Prostaglandin D synthase (beta-trace) in healthy human sleep. Sleep 2004, 27(5), 867-74.
28. Sadakata, T.; Kakegawa, W.; Mizoguchi, A.; Washida, M.; Katoh-Semba, R.; Shutoh, F.; Okamoto, T.; Nakashima, H.; Kimura, K.; Tanaka, M.; Sekine, Y.; Itohara, S.; Yuzaki, M.; Nagao, S.; Furuichi, T. Impaired cerebellar development and function in mice lacking CAPS2, a protein involved in neurotrophin release. J. Neurosci. 2007, 27(10), 472-82.
29. Brun, P.; Begou, M.; Andrieux, A.; Mouly-Badina, L.; Clerget, M.; Schweitzer, A.; Scarna, H.; Renaud, B.; Job, D.; Suaud-Chagny, M.F. Dopaminergic transmission in STOP null mice. J. Neurochem. 2005, 94(1), 63-73.
30. Deltour, L.; Foglio, M.H.; Duester, G. Metabolic deficiencies in alcohol dehydrogenase Adh1, Adh3, and Adh4 null mutant mice. Overlapping roles of Adh1 and Adh4 in ethanol clearance and metabolism of retinol to retmoic acid. J. Biol. Chem. 1999, 274(24), 16796-801.
31. Popova, N.K.; Vishnivetskaya, G.B.; Ivanova, E.A.; Skrinskaya, J.A.; Seif, I. Altered behavior and alcohol tolerance in transgenic mice lacking MAO A: A comparison with effects of MAO A inhibitor clorgyline. Pharmacol. Biochem. Behav. 2000, 67(4), 719-27.
32. Kim, J.S.; Coon, S.L.; Blackshaw, S.; Cepko, C.L.; Moller, M.; Mukda, S.; Zhao, W.Q.; Charlton, C.G.; Klein, D.C. Methionine adenosyltransferase:aDrenergic-cAMP mechanism regulates a daily rhythm in pineal expression. J. Biol. Chem. 2005, 280(1), 677-84.
33. Qu, W.M.; Huang, Z.L.; Xu, X.H.; Aritake, K.; Eguchi, N.; Nambu, F.; Narumiya, S.; Urade, Y.; Hayaishi, O. Lipocalin-type prostaglandin D synthase produces prostaglandin D2 involved in regulation of physiological sleep. Proc. Natl Acad Sci. USA 2006, 103(47), 17949-54.
34. Kapfhamer, D.; Vatladares, O.; Sun, Y.; Nolan, P.M.; Rux, J.J.; Arnold, S.E.; Veasey, S.C.; Bucan, M. Mutations in Rab3a alter circadian period and homeostatic response to sleep loss in the mouse. Nat. Genet. 2002, 32(2), 290-5.
35. Wisor, J.P.; Wurts, S.W.; Hall, F.S.; Leach, K.P.; Murphy, D.L.; Uhl, G.R.; Edgar, D.M. Altered rapid eye movement sleep timing in serotonin transporter knockout mice. Neuroreport 2003, 14(2), 233-8.
36. Urade, Y.; Eguchi, N.; Qu, W.M.; Sakata, M.; Huang, Z.L.; Chen, J.F.; Schwarzschild, M.A.; Fink, J.S.; Hayaishi, O. Sleep regulation in adenosine A2A receptor-deficient mice. Neurology 2003, 61(11 Suppl 6), S94-S96.
37. Cota, D. CB1 receptors: Emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab. Res. Rev. 2007, 23(7), 507-17.
38. Narita, M.; Soma, M.; Tamaki, H.; Narita, M.; Suzuki, T. Intensification of the development of ethanol dependence in mice lacking doparnine D(3) receptor. Neurosci. Lett. 2002, 324(2), 129-32.
39. Yujnovsky, I.; Hirayama, J.; Doi, M.; Borrelli, E.; Sassone-Corsi, P. Signaling mediated by the dopamine D2 receptor potentiates circadian regulation by CLOCK:BMAL1. Proc. Natl. Acad. Sci. USA 2006; 103(16), 6386-91.
40. Blednov, Y.A.; Jung, S.; Alva, H.; Wallace, D.; Rosahl, T.; Whiting, P.J.; Harris, R.A. Deletion of the alphal or beta2 subunit of GABAA receptors reduces actions of alcohol and other drugs. J. Pharmacol. Exp. Ther. 2003, 304(1), 30-6.
41. Szentirmai, E.; Kapas, L.; Sun, Y.; Smith, R.G.; Krueger, J.M. Spontaneous sleep and homeostatic sleep regulation in ghrelin knockout mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 293(1), R510-R517.
42. Huang, Z.L.; Mochizuki, T.; Qu, W.M.; Hong, Z.Y.; Watanabe, T.; Urade, Y.; Hayaishi, O. Altered sleep-wake characteristics and lack of arousal response to H3 receptor antagonist in histamine H1 receptor knockout mice. Proc. Natl. Acad Sci. USA 2006, 103(12), 4687-92.
43. Goutagny, R.; Comte, J.C.; Salvert, D.; Gomeza, J.; Yamada, M.; Wess J.; Luppi, P.H.; Fort, P. Paradoxical sleep in mice lacking M3 and M2/M4 muscarinic receptors. Neuropsychobiology 2005, 52(3), 140-6.
44. Naveilhan, P.; Hassani, H.; Lucas, G.; Blakeman, K.H.; Hao, J.X.; Xu, X.J.; Wiesenfeld-Hallin, Z.; Thoren, P.; Ernfors, P. Reduced antinociception and plasma extravasation in mice lacking a neuropeptide Y receptor. Nature 2001, 409(6819), 513-7.
45. Panda, S.; Sato, T.K.; Castrucci, A.M.; Rollag, M.D.; DeGrip, W.J.; Hogenesch, J.B.; Provencio, I.; Kay, S.A. Melanopsin (Opn4) requirement for normal light-induced circadian phase shifting. Science 2002, 298(5601), 2213-6.
46. Harmar, A.J.; Marston, H.M.; Shen, S.; Spratt, C.; West, K.M.; Sheward, W.J.; Morrison, C.F.; Dorin, J.R.; Piggins, H.D.; Reubi, J.C.; Kelly, J.S.; Maywood, E.S.; Hastings, M.H. The VPAC(2) receptor is essential for circadian function in the mouse suprachiasmatic nuclei. Cell 2002, 109(4), 497-508.
47. Anderson, M.P.; Mochizuki, T.; Xie, J.; Fischler, W.; Manger, J.P.; Talley, E.M.; Scammell, T.E.; Tonegawa, S. Thalamic Cav3.1 T-type Ca2+ channel plays a crucial role in stabilizing sleep. Proc. Natl. Acad. Sci. USA 2005, 102(5), 1743-8.
48. Meredith, A.L.; Wiler, S.W.; Miller, B.H.; Takahashi, J.S.; Fodor, A.A.; Ruby, N.F.; Aldrich, R.W. BK calcium-activated potassium channels regulate circadian behavioral rhythms and pacemaker output. Nat. Neurosci. 2006 9(8), 1041-9.
49. Joho, R.H.; Marks, G.A.; Espinosa, F. Kv3 potassium channels control the duration of dfferent arousal states by distinct stochastic and clock-like mechanisms. Eur. J. Neurosci. 2006, 23(6), 1567-74.
50. Douglas, C.L.; Vyazovskiy, V.V.; Southard, T.L.; Chiu, S.Y.; Messing, A.; Tononi, G.; Cirelli, C. Sleep in Kcna2 knockout mice. BMC Biol. 2007, 5(1), 42.
51. Kondratov, R.V.; Chernov, M.V.; Kondratova, A.A.; Gorbacheva, V.Y.; Gudkov, A.V.; Antoch, M.P. BMAL1-dependent circadian oscillation of nuclear CLOCK: Posttranslational events induced by dimerization of transcriptional activators of the mammalian clock system. Genes Dev. 2003, 17(15), 1921-32.
52. Bunger, M.K.; Wilsbacher, L.D.; Moran, S.M.; Clendenin, C.; Radcliffe, L.A.; Hogenesch, J.B.; Simon, M.C.; Takahashi, J.S.; Bradfield, C.A. Mop3 is an essential component of the master circadian pacemaker in mammals. Cell 2000, 103(7), 1009-17.
53. Murakami, D.M.; Erkman, L.; Hermanson, O.; Rosenfeld, M.G.; Fuller, C.A. Evidence for vestibular regulation of autonomic functions in a mouse genetic model. Proc. Natl. Acad. Sci. USA 2002, 99(26), 17078-82.
54. Vitaterna, M.H.; King, D.P.; Chang, A.M.; Kornhauser, J.M.; Lowrey, P.L.; McDonald, J.D.; Dove, W.F.; Pinto, L.H.; Turek, F.W.; Takahashi, J.S. Mutagenesis and mapping of a mouse gene, Clock, essential for circadian behavior. Science 1994, 264(5159), 719-25.
55. Maldonado, R.; Smadja, C.; Mazzucchelli, C.; Sassone-Corsi, P. Altered emotional and locomotor responses in mice deficient in the transcription factor CREM. Proc. Natl. Acad. Sci. USA 1999, 96(24), 14094-9.
56. van der Horst, G.T.; Muijtjens, M.; Kobayashi, K.; Takano, R.; Kanno, S.; Takao, M.; de Wit J.; Verkerk, A.; Eker, A.P.; Van Leenen, D.; Buijs, R.; Bootsma, D.; Hoeijmakers, J.H.; Yasui, A. Mammalian Cry1 and Cry2 are essential for maintenance of circadian rhythms. Nature 1999, 398(6728), 627-30.
57. Franken, P.; Lopez-Molina, L.; Marcacci, L.; Schibler, U.; Tafti, M. The transcription factor DBP affects circadian sleep consolidation and rhythmic EEG activity. J Neurosci. 2000, 20(2), 617-25.
58. Wee, R.; Castrucci, A.M.; Provencio, I.; Gan, L.; Van Gelder, R.N. Loss of photic entrainment and altered free-running circadian rhythms in math5-/- mice. J. Neurosci. 2002, 22(23), 10427-33.
59. Dudley, C.A.; Erbel-Sieler, C.; Estill, S.J.; Reick, M.; Franken, P.; Pitts, S.; McKnight S.L. Altered patterns of sleep and behavioral adaptability in NPAS2-deficient mice. Science 2003, 301(5631), 379-83.
60. Zheng, B.; Albrecht U.; Kaasik, K.; Sage, M.; Lu, W.; Vaishnav, S.; Li, Q.; Sun, Z.S.; Eichele, G.; Bradley, A.; Lee, C.C. Nonredundant roles of the mPerl and mPer2 genes in the mammalian circadian clock. Cell 2001, 105(5), 683-94.
61. Bae, K.; Jin, X.; Maywood, E.S.; Hastings, M.H.; Reppert, S.M.; Weaver, D.R. Differential functions of mPer1, mPer2, and mPer3 in the SCN circadian clock. Neuron 2001, 30(2), 525-36.
62. Xie, W.; Barwick, JL.; Downes, M.; Blumberg, B.; Simon, C.M.; Nelson, M.C.; Neuschwander-Tetri, B.A.; Brunt, E.M.; Guzelian, P.S.; Evans, R.M. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 2000, 406(6794), 435-9.
63. Inoue, S.; Honda, K.; Komoda, Y.; Uchizono, K.; Ueno, R.; Hayaishi, O. Differential Sleep-Promoting Effects of 5 Sleep Substances Nocturnally Infused in Unrestrained Rats. Proc. Natl. Acad. Sci. USA Biol. Sci. 1984, 81(19), 6240-4.
64. Onoe, H.; Ueno, R.; Fujita, I.; Nishino, H.; Oomura, Y.; Hayaish, O. Prostaglandin D2, a cerebral sleep-inducing substance in monkeys. Proc. Natl. Acad. Sci. USA 1988, 85(11), 4082-6.
65. Mizoguchi, A.; Eguchi, N.; Kimura, K.; Kiyohara, Y.; Qu, W.M.; Huang, Z.L.; Mochizuki, T.; Lazarus, M.; Kobayashi, T.; Kaneko, T.; Narumiya, S.; Urade, Y.; Hayaishi, O. Dominant localization of prostaglandin D receptors on arachnoid trabecular cells in mouse basal forebrain and their involvement in the regulation of non-rapid eye movement sleep. Proc Natl. Acad. Sci. USA 2001, 98(20), 11674-9.
66. Hayaishi, O.; Urade, Y.; Eguchi, N.; Huang, Z.L. Genes for prostaglandin D synthase and receptor as well as adenosine A(2A) receptor are involved in the homeostatic regulation of NREM sleep. Arch. Italiennes de Biol. 2004, 142(4), 533-9.
67. Barcelo, A.; de la Pena, M.; Barbe, F.; Pierola, J.; Bosch, M.; Agusti, A.G.N. Prostaglandin D synthase (beta trace) levels in sleep apnea patients with and without sleepiness. Sleep Med. 2007, 8(5), 509-11.
68. Pentreath, V.W.; Rees, K.; Owolabi, O.A.; Philip, K.A.; Dona, F. The somnogenic T lymphocyte suppressor prostaglandin D2 is selectively elevated in cerebrospinal fluid of advanced sleeping sickness patients. Trans. Royal Soc. Trop. Med. Hygiene 1990, 84, 795-9.
69. Baker, S.K.; Zee, P.C. Circadian Disorders of the Sleep-Wake Cycle. In: Kryger MH, Roth T, Dement WC, editors. Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia: W.B. Saunders Company; 2000. p. 606-14.
70. Archer, S.N.; Robillard, D.L.; Skene, D.J.; Smits, M.; Williams, A.; Arendt, J.; von Schantz, M. A length polymrphism in the circadian clock gene Per3 is linked to delayed sleep phase syndrome and extreme diurnal preference. Sleep 2003, 26, A109.
71. Groeger, J.; Lo, J.; Viola, A.; von Schantz, M.; Archer, S.; Dijk, D. PER3 polymorphism predictsusceptibility to sleep deprivation-induced impairment of early morning executive performance. Sleep 2007, 30, A54.
72. Viola, A.U.; Archer, S.N.; James, L.M.; Groeger, J.A.; Lo, J.C.; Skene, D.J.; von Schantz, M.; Dijk, D.J. PER3 polymorphism predicts sleep structure and waking performance. Curr. Biol. 2007, 17(7), 613-8.
73. Viola, A.U.; Archer, S.N.; Groeger, J.A.; Skene, D.J.; von Schantz, M.; Dijk, D.J. Polymorphism in the clock gene PER3 predicts sleep structure and EEG power spectra. J. Sleep Res. 2006, 53.
74. Jones, K.H.; Ellis, J.; von Schantz, M.; Skene, D.J.; Dijk, D.; Archer, S.N. Age-related change in the association between a variable number tandem repeat polymorphism in the (PER3) gene and preferred timing of sleep and waking activities. J. Sleep Res. 2006, 15, 97-8.
75. Hall JC. Genetics and Molecular Biology of Rhythms in Drosophila and Other Insects. Advances in genetics 2003;48:1-280.
76. Maywood, E.S.; O'Brien, J.A.; Hastings, M.H. Expression of mCLOCK and Other Circadian Clock-Relevant Proteins in the Mouse Suprachiasmatic Nuclei. J. Neuroendocrinol. 2003, 15(4), 329-34.
77. O'Neill, M.J.; Dix, S. AMPA receptor potentiators as cognitive enhancers. Idrugs 2007, 10(3), 185-92.
78. Tollefson, G.; Mansbach, H.; Deadwyler, S. Is translational research monkey business: The journey of a novel AMPAKINE (CX 717) from primate to a human phase 1B study with a cognitive impairment model. Neuropsychopharmacology 2005, 30, S83-S84.
79. Kopp, C.; Longordo, F.; Nicholson, J.R.; Luthi, A. Insufficient sleep reversibly alters bidirectional synaptic plasticity and NMDA receptor function. J. Neurosci. 2006, 26(48), 12456-65.
80. McKernan, R.M.; Whiting, P.J. Which GABA(A)-receptor subtypes really occur in the brain? Trends Neurosci. 1996, 19(4), 139-43.
81. Barnard, E.A.; Skolnick, P.; Olsen, R.W.; Mohler, H.; Sieghart, W.; Biggio, G.; Braestrup, C.; Bateson, A.N.; Langer, S.Z. International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acid(A) receptors: Classification on the basis of subunit structure and receptor function. Pharmacol. Rev. 1998, 50(2), 291-313.
82. Macdonald, R.L.; Olsen, R.W. Gaba(A) Receptor Channels. Ann. Rev. Neurosci. 1994, 17, 569-602.
83. Jouvet M.; MOUNIER D. [Effect of lesions of the pontile reticular formation on sleep in the cat]. C R Seances Soc. Biol Fil. 1960, 154, 2301-5.
84. Lin, J.S.; Sakai, K.; Jouvet, M. Hypothalarno-Preoptic Histaminergic Projections in Sleep-Wake Control in the Cat. Eur. J. Neurosci. 1994, 6(4), 618-25.
85. Lovenberg, T.W.; Roland, B.L.; Wilson, S.J.; Jiang, X.X.; Pyati, J.; Huvar, A.; Jackson, M.R.; Erlander, M.G. Cloning and functional expression of the human histamin H-3 receptor. Mol. Pharmacol. 1999, 55(6), 1101-7.
86. McCarley, R.W.; Massaquoi, S.G. Neurobiological structure of the revised limit cycle reciprocal interaction model of REM cycle control. J. Sleep Res. 1992, 1(2), 132-7.
87. Bal, T.; Mccormick, D.A. Mechanisms of Oscillatory Activity in Guinea-Pig Nucleus-Reticularis Thalami In-Vitro - A Mammalian Pacemaker. J. Physiol. London 1993, 468, 669-91.
88. Mccormick, D.A.; Wang, Z. Serotonin and Noradrenaline Excite Gabaergic Neurons of the Guinea-Pig and Cat Nucleus Reticularis Thalami. J. Physiol.-London 1991, 442, 235-55.
89. Jones, B.E. Paradoxical Sleep and Its Chemical Structural Substrates in the Brain. Neuroscience 1991, 40(3), 637-56.
90. Jones, B.E. Arousal systems. Front. Biosci. 2003, 8, 438-S451.
91. Mccormick, D.A. Cellular Mechanisms Underlying Cholinergic and Noradrenergic Modulation of Neuronal Firing Mode in the Cat and Guinea-Pig Dorsal Lateral Geruculate-Nucleus. J. Neurosci. 1992, 12(1), 278-89.
92. Mccormick, D.A.; Pape, H.C.; Williamson, A. Actions of Norepinephrine in the Cerebral-Cortex and Thalamus - Implications for Function of the Central Noradrenergic System. Prog. Brain Res. 1991, 88, 293-305.
93. Basheer, R.; Strecker, R.E.; Thakkar, UK; McCarley, R.W. Adenosine and sleep-wake regulation. Prog. Neurobiol. 2004, 73(6), 379-96.
94. Hohagen, F.; Rink, K.; Kappler, C.; Schramm, E.; Riemann, D.; Weyerer, S.; Berger, M. Prevalence and treatment of insomnia in general practice. A longitudinal study. Eur. Arch. Psychiatry. Clin. Neurosci. 1993, 242(6), 329-36.
95. Walsh, J.K. Pharmacologic management of insomnia. J. Clin. Psychiatry 2004, 65(Suppl 16), 41-5.
96. Roehrs, T.; Roth, T. 'Hypnotic' prescription patterns in a large managed-care population. Sleep Med. 2004, 5(5), 463-6.
97. Greenblatt, D.J.; Harmatz J.S.; von Moltke, L.L.; Ehrenberg, B.L.; Harrel, L.; Corbett, K.; Counihan, M.; Graf, J.A.; Darwish, M.; Mertzanis, P.; Martin, P.T.; Cevallos, W.H.; Shader, R.I. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin. Pharmacol. Ther. 1998, 64(5), 553-61.
98. Barbera, J.; Shaprio, C. Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Safety 2005, 28(4), 301-18.
99. Chen, H.J. Spontaneous and Melatonin-Induced Testicular Regression in Male Golden-Hamsters - Augmented Sensitivity of the Old Male to Melatonin Inhibition. Neuroendocrinology 1981, 33(l), 43-6.
100. Lincoln, G.A.; Andersson, H Loudon A. Clock genes in calendar cells as the basis of annual timekeeping in mammals - a unifying hypothesis. J. Endocrinol. 2003, 179(1), 1-13.
101. Sack, R.L.; Hughes, R.J.; Edgar, D.M.; Lewy, A.J. Sleeppromoting effects of melatonin: At what dose, in whom, under what conditions, and by what mechanisms? Sleep 1997, 20(10), 908-15.
102. Erman, M.; Seiden, D.; Zammit, G.; Sainati, S.; Zhang, J. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med. 2006, 7(l), 17-24.
103. Roth, T.; Seiden, D.; Sainati, S.; Wang-Weigand, S.; Zhang, J.; Zee, P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med. 2006, 7(4), 312-8.
104. Wisor, J.P.; Eriksson, K.S. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience 2005, 132(4), 1027-34.
105. Scrima, L.; Hartman, P.G.; Johnson, F.H.; Thomas, E.E.; Hiller, F.C. The Effects of Gamma-Hydroxybutyrate on the Sleep of Narcolepsy Patients - A Double-Blind-Study. Sleep 1990 13(6), 479-90.
106. Black, J.; Emsellem, H.; Feldman, N.; Hagaman, M.; Hayduk, R.; Kathawalla, S.; Lankford, D.; Marmion, L.; Mitler, M.; Pascualy, R.; Sahota, P.; Scharf, M.; Scrima, L.; Swick, T.; Ware, J. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms. J. Toxicol. Clin. Toxicol. 2003, 41(2), 131-5.
107. Sharpley, A.L.; Elliott, J.M.; Attenburrow, M.J.; Cowen, P.J. Slow wave sleep in humans: Role of 5-HT2A and 5-HT2C receptors. Neuropharmacology 1994, 33(3-4), 467-71.
108. Wijtmans, M.; Leurs, R.; de Esch, I. Histamine H-3 receptor ligands break ground in a remarkable plethora of therapeutic areas. Expert Opin. Invest. Drugs 2007, 16(7)967-85.